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Abstract: I n t r o d u c t i o n: Th is study focused on the assessment of HSP-10, HSP-27 and PSG-11 which 
are one of the fi rst detectable serum pregnancy proteins. Contrary to ultrasound imaging, biochemical 
methods allow to clarify the pathogenesis and pathomechanism of high-risk pregnancies, fetal anomalies, 
and abnormal fetal implantation. Early serum concentration estimation of HSP-10, HSP-27 and PSG-11 
may be very useful not only in prognosis of pregnancies of unknown localization (PUL), but also as mark-
ers of ectopic pregnancies.
O b j e c t i v e s: Th e aim of the study was to evaluate the expression of HSP-10, HSP-27, PSG-11 implanta-
tion proteins in ectopic and eutopic pregnancies, and their mutual correlations.
P a t i e n t s  a n d  M e t h o d s: Th e study involved 42 healthy women who were hospitalized, due to 
symptoms of imminent miscarriage, risk of spontaneous abortion, or the diagnosis of an ectopic preg-
nancy. Th e subjects were subdivided into two equal groups of 21 women who consented to participate 
in this clinical trial. Biochemical assays were performed involving PSG-11, HSP-27, and HSP-10 serum 
concentration.
R e s u l t s: Serum concentration levels of HSP-10, HSP-27, and PSG-11 were signifi cantly higher in preg-
nancies at risk of spontaneous abortion as compared to ectopic pregnancies.
C o n c l u s i o n s: Th e results of the study indicate high value of PSG-11, HSP-27 and HSP-10 serum con-
centrations as predictors of correct implantation site. Th is may be very useful in prognosis of pregnancies 
of unknown localization (PUL) and early conservative/surgical ectopic pregnancies treatment if necessary 
to preserve maximum fertility.
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Introduction
Biochemical studies, especially hormonal assays, constitute a powerful, albeit secondary, 
diagnostic tool for the detection of ectopic pregnancies and pregnancies at a  high risk 
of spontaneous abortion/miscarriage. In contemporary medicine, the rapidly evolving 
ultrasound has become a vital instrument of great diagnostic sensitivity and specifi city. 
Serial determination of proteins and fetal steroids, along with ultrasonographic specifi -
city and sensitivity, allows not only to diagnose an ectopic pregnancy with a  95–99% 
accuracy, but also to establish the prognosis of high-risk early eutopic pregnancies. Th e 
most commonly monitored protein of placental origin is β-subunit of human chorionic 
gonadotropin (β-hCG) [1, 2], while progesterone remains the main monitored steroid 
hormone [3]. Serum profi les of these substances are most oft en used to confi rm preg-
nancy, monitor and forecast further embryonic development, as well as to evaluate pla-
cental effi  ciency and the wellbeing of the developing fetus [4]. A widespread application 
of biophysical methods such as fetal ultrasound monitoring is the reason why biochem-
ical monitoring has become largely underestimated. Contrary to ultrasound imaging, 
biochemical methods allow to clarify the pathogenesis and pathomechanism of high-
risk pregnancies, fetal anomalies, and abnormal fetal implantation. Detection of protein 
markers present in the serum of pregnant women constitutes the foundation of a non-
invasive biochemical monitoring of proper blastocyst implantation and fetal health [5]. 
Serum concentrations of certain proteins in pregnancy i.e. PSG9 (pregnancy-specifi c be-
ta-1-glycoprotein 9), PSG11 (pregnancy-specifi c beta-1-glycoprotein 11), PAPP-A (preg-
nancy-associated plasma protein A), PSG3 (pregnancy-specifi c beta-1-glycoprotein  3), 
HSP-10 (heat-shock protein 10), HSP-27 (heat-shock protein 27), Ca 125, as well as in-
hibins A and B, allow to assess the site of implantation and ongoing pregnancy [6–9]. 
Our study focused on the assessment of HSP-10, which is encoded on chromosome  2 
and is an oligomer of 6 to 8 identical subunits [10]. Furthermore, HSP-10 in combina-
tion with HSP-60 impedes its ATPase activity. HSP-10 is present in the maternal se-
rum aft er fertilization of the ovum. Th e media used in the IVF-ET demonstrate the 
presence of HSP-10 protein 48 hours aft er fertilization [11]. Its presence may also be 
demonstrated in the cervical mucus and the amniotic fl uid [12, 13]. Th e current genera-
tion of pregnancy tests focuses on the presence of β-subunit of chorionic gonadotropin 
(β-hCG), which appears in the serum no earlier than 6 days aft er fertilization [14]. It is 
accepted that HSP-10 is the earliest detectable protein in maternal serum early in preg-
nancy [15, 16]. Apart from implantation processes, HSP-10 is involved in carcinogenesis 
of colorectal cancer [17, 18], and may be used as a marker of remission in ovarian can-
cer [19]. In addition, HSP-10 further exhibits anti-infl ammatory activity, most likely via 
interactions with extracellular HSP-60 protein fraction [20].
HSP-27 is yet another protein which is encoded by the HSPB1 gene, located on 
chromosome 3. It is found in many types of tissues, especially muscle tissue, where 
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it is found in high concentrations in muscle tissue cytosol, but also appears in the 
perinuclear vicinity, reticulum, and nucleus. Th e main function of this protein is to 
ensure thermotolerance and cytoprotection of cells exposed to stress. HSP-27 is also 
involved in inhibition of apoptosis [21] and its decreased expression in systemic lupus 
erythematosus pregnant patients is associated with higher miscarriage rate [22, 23]. 
Another function of this protein is cell purifi cation by the activation of proteasomes, 
which degrade irreversibly denatured proteins and stimulate the pathway of 
NF-kappa-B, which is important in the process of implantation, development of 
immune tolerance, and carcinogenesis [24, 25]. Th e protein is present in the placenta 
and there is a visible decrease in its concentration as the labor progresses [26].
PSG-11 (pregnancy specifi c glycoprotein b-11) was the last investigated marker. 
In order to achieve adequate pregnancy development in mammalian species, a correct 
sequence of vascular processes between the embryo and the decidua ought to take 
place. Th is increased blood fl ow is associated with proper angiogenesis, vasodilation, 
and vascular remodeling [27, 28]. Proteins from the PSG family take an active part 
in that process by interacting with VEGF (vasoendothelial growth factor) and TGF-b 
pathways [29]. Previous studies reported lower concentrations of proteins from 
the PSG family to be associated with reduced fetal growth [30, 31]. Furthermore, 
a  relationship between abnormally low concentrations of PSG proteins and the 
development of preeclampsia was also reported [32]. So far, the literature reports have 
failed to identify the exact steps of the correlation cascade when these proteins arrive 
at their aberrant expression, resulting in abnormal migration and implantation of the 
embryo. 
Patient and methods
Th e aim of the study was to evaluate the expression of HSP-10, HSP-27, PSG-11 im-
plantation proteins in ectopic and eutopic pregnancies, and their mutual correlations.
The study involved 42 healthy women who were hospitalized at the Clinic 
of Gynecological Endocrinology, Jagiellonian University Medical College, due to 
symptoms of imminent miscarriage, risk of spontaneous abortion, or the diagnosis 
of an ectopic pregnancy. The subjects were subdivided into two equal groups of 
21 women who consented to participate in this clinical trial. Biochemical assays were 
performed at the Department of Biochemistry, UJCM Children’s Hospital.
Th e following were performed in all participants:
— detailed OB-GYN interview
— physical examination as well as a complete OB-GYN exam using ultrasound
— blood pressure measurements
— anthropometric measurements, including height and weight
— biochemical tests involving PSG-11, HSP-27, and HSP-10.
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Inclusion criteria: Healthy women, regardless of age or ethnicity, diagnosed with 
pregnancy of incorrect location (e.g. ectopic tubal pregnancy, ovarian, abdominal, or 
cervical) or intrauterine pregnancy at risk of miscarriage/spontaneous abortion with 
symptoms including vaginal bleeding, pain in the mid-lower abdomen, as well as 
‘silent’ dilatation of the cervix, were included in the study.
Exclusion criteria: Th e study excluded women currently taking medication due 
to the following coexisting diseases: hypertension, coronary heart disease, diabetes, 
active and chronic infl ammation, autoimmune diseases, liver disease, kidney disease, 
cancer, thrombophlebitis or history of venous thromboembolic disease, cholelithiasis 
without history of cholecystectomy, illnesses involving seizures including epilepsy, 
and migraine. Smoking and alcohol consumption were included in the interview.
Biochemical assays were performed at the Department of Laboratory Diagnostics, 
Children’s Clinical Hospital, Jagiellonian University. Testing and analyses of the 
implantation markers were carried out with enzyme-linked immunosorbent assay 
(ELISA) using reagent kits from Stressgen Biotechnologies. Each assay was performed 
in duplicate. Th e standard curve was generated for each set of assays from standards 
of known concentrations for each protein.
In order to determine statistical signifi cance of diff erences between the groups, 
as well as the possible correlations between them, the following tests were used to 
assess the variables: Student’s t test for independent variables, Pearson’s correlation 
coefficient, and chi-square test. Written informed consent was obtained from all 
participants. Local Ethics Committee approved of the study.
Results
Th e study included 42 women: 21 diagnosed with ectopic pregnancy and 21 with 
pregnancies at risk of miscarriage. Mean β-HCG concentration in both groups was 
7300 IU/mL. Mean maternal age was 28 years. No diff erences between BMI and duration 
of pregnancy calculated from the date of the last menstrual cycle were found (Table 1).
Table 1. Study group characteristics.
Characteristics Patients with ectopic pregnancy
Patients with risk 
of miscarrige
Number of cases — n 21 21
Mean age (min-max) 28 (23–25) 28 (22–23)
Mean BMI (min-max) 24.4 (17.9–34.0) 22.8 (17.8–30.1)
Percentage of obese patients (BMI >30) 9.6% (n = 2) 4.8% (n = 1)
Percentage of underweight patients (BMI <18.5) 4.8% (n = 1) 9.6% (n = 2)
Weeks of pregnancy 6–8 6–9
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However, lower concentrations of all proteins were observed in the ectopic 
pregnancy group. 
Mean serum HSP-10 concentrations were 65.29 ug/ml (SD 59.32) and 120.12 ug/ml 
(SD 39.82), P = 0.001 in the ectopic and eutopic pregnancy groups, respectively 
(Fig. 1). Th e diff erence in mean serum concentrations was 54.95 ug/ml (95% CI for the 
diff erence of 42.85–66.82).
Fig. 1. HSP-10 serum concentrations in women with ectopic pregnancy and early eutopic pregnancy.
Mean serum HSP-27 concentrations were 33.24 ug/ml (SD 31.35) and 66.55 ug/ml 
(SD 13.97), P <0.001 in the ectopic and eutopic pregnancy groups, respectively (Fig. 2). 
The difference in mean serum concentrations was 33.31 ug/ml (95% CI for the 
diff erence of 25.84–40.73).
Fig. 2. HSP-27 serum concentrations in women with ectopic pregnancy and early eutopic pregnancy.
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Mean serum PSG-11 concentrations were 13.34 ug/ml (SD 14.73) and 30.44 ug/ml 
(SD 8.8), P <0.001 in the ectopic and eutopic pregnancy groups, respectively (Fig. 3). 
The difference in mean serum concentrations was 17.10 ug/ml (95% CI for the 
diff erence of 12.90–21.25).
Fig. 3. PSB-11 serum concentrations in women with ectopic pregnancy and early eutopic pregnancy.
Concentration levels of HSP-10, HSP-27, and PSG-11 were signifi cantly higher in 
pregnancies at risk of spontaneous abortion as compared to ectopic pregnancies.
A linear regression model was created in order to assess the impact of maternal 
age, BMI, and gestational week on serum protein concentration (Table 2).
HSP-10:  Th e  linear  regression  model  displayed  signifi cance  only  in  the 
diagnosis of ectopic pregnancy or pregnancies at risk of spontaneous abortion. 
Maternal age, BMI, and gestational age were not included in the fi nal model. Th e 
resulting fi nal regression equation explains only 22% of the variation, with a standard 
error of 50.5 (representing 54% of the average protein levels in the group of 
respondents), signifying a need to look for other factors aff ecting the level of HSP-10. 
HSP-27:  Th e  linear  regression  model  displayed  signifi cance  only  in  the 
diagnosis of ectopic pregnancy or pregnancies at risk of spontaneous abortion. 
Maternal age, BMI, and gestational age were not included in the final model. 
The resulting final regression equation explains only 31% of the variation, with 
standard error of 24.37 (representing 49% of the average protein levels in the group 
of respondents), signifying a  need to look for other factors aff ecting the level of 
HSP-27.
PSG-11: Th e linear regression model displayed signifi cance only in the diagnosis 
of ectopic pregnancy or pregnancies at risk of spontaneous abortion. Maternal age, 
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Table 2. Impact of maternal age, BMI, and gestational week on serum protein concentration.
Parameter Regression for HSP-10 Regression for HSP-27 Regression for PSBG-11
Age — P  0.227  0.702  0.109
BMI — P  0.373  0.776  0.876
Pregnancy week — P  0.815  0.499  0.856
Diagnosis <0.001 <0.001 <0.001
P value  0.017  0.003  0.001
Coeffi  cient of deter-
mination (R2) of the 
output model
19% 27% 33%
P value of the fi nal 
model  0.001 <0.001 <0.001
Coeffi  cient of deter-




(Mean %) 50.5 (54%) 24.37 (49%) 12.13 (55%)
regression equation explains only 33% of the variation, with standard error of 
12.13 (representing 55% of the average protein levels in the group of respondents), 
signifying a need to look for other factors aff ecting the level of PSG-11.
Discussion
Biochemical diagnosis is the key to a  better understanding of the processes of 
implantation in both, ectopic and eutopic pregnancies. In this study, signifi cantly 
higher levels of HSP-10, HSP-27, and PSG-11 implantation proteins were observed 
in pregnancies with normal site of implantation. Furthermore, by improving 
detection of these proteins, the eff ect of treatment of ectopic pregnancies may be 
monitored, especially in pregnancies of unknown localization (PUL). Early diagnosis 
of PUL constitutes the greatest challenge. Th e earlier the ectopic pregnancy is 
diagnosed, the sooner the conservative treatment with methotrexate can be applied. 
If introduced early, the conservative treatment can be exceptionally eff ective. 
Additionally, by minimizing the dosage of methotrexate, the side eff ects are also 
minimized, resulting in unimpaired fertility [33]. Low level of variation coeffi  cient 
in determining protein levels and high standard error suggest the existence of 
an additional, yet to be discovered, variable which aff ects the level of protein in 
ectopic pregnancies or gestations at risk of miscarriage/spontaneous abortion. 
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Further studies of PUL cases are required to confi rm the results obtained in 
this study.
At present, lack of rapidly available laboratory diagnostics, which might produce 
the results of serum protein concentrations of HSP-10, HSP-27, and PSG-11 in <24 
hours, constitutes the most serious limitation.
Th e results of the study indicate high value of PSG-11, HSP-27 and HSP-10 serum 
concentrations as predictors of correct implantation site. Th is may be very useful 
in prognosis of pregnancies of unknown localization (PUL) and early conservative/
surgical ectopic pregnancies treatment if necessary to preserve maximum fertility.
Contribution statement
Jakub Wyroba and Agnieszka Rajtar-Ciosek conceived the idea for the study. Jakub 
Wyroba and Olga Kacalska-Jansen contributed to the design of the research. All au-
thors were involved in data collection. Dorota Babczyk analyzed the data. Andrzej 
Zmaczyński coordinated funding for the project. All authors edited and approved the 
fi nal version of the manuscript.
Acknowledgments
Th is work was supported by the Ministry of Education (MNiSW) of the Republic of 
Poland (grant numbers K/ZDS/004550 and K/DSC/000746).
Confl ict of interest
None declared.
References
1.  Cabar F.R., Pereira P.P., Schultz R., Zugaib M.: Predictive factors of trophoblastic invasion into the 
ampullary region of the tubal wall in ectopic pregnancy. Hum Reprod. 2006; 21: 226–243.
2.  Mol B.W., Lijmer J.G., Ankum W.M., van der Veen F., Bossuyt P.M.: Th e accuracy of single serum 
progesterone measurement in the diagnosis of ectopic pregnancy: a  meta-analysis. Hum Reprod. 
1998; 13: 3220–3227.
3.  Cabar F.R., Fettback P.B., Pereira P.P., Zugaib M.: Serum markers in the diagnosis of tubal pregnancy. 
Clinics 2008; 63: 701–708.
4.  Cheng Y.H., Imir A., Suzuki T., et al.: SP1 and SP3 mediate progesterone-dependent induction of the 
17beta hydroxysteroid dehydrogenase type 2 gene in human endometrium. Biol Reprod. 2006; 75: 
605–614.
5.  Spitzer M., Pinto A.B., Dasgupta R., Benjamin F.: Early diagnosis of ectopic pregnancy: can we do it 
accurately using a biochemical profi le? J Womens Health Gend Based Med. 2000; 9: 537–544.
 Markers of implantation in ectopic and high-risk early eutopic pregnancies 49
 6.  Nyegaard M., Overgaard M.T., Su Y.Q., et al.: Lack of functional pregnancy-associated plasma 
protein-A (PAPPA) compromises mouse ovarian steroidogenesis and female fertility. Biol Reprod 
Biol Reprod. 2010; 82 (6): 1129–1138.
 7.  Ugurlu E.N., Ozaksit G., Karaer A., Zulfi karoglu E., Atalay A., Ugur M.: Th e value of vascular 
endothelial growth factor, pregnancy-associated plasma protein-A, and progesterone for early 
differentiation of ectopic pregnancies, normal intrauterine pregnancies, and spontaneous 
miscarriages. Fertil Steril. 2009; 91: 1657–1661.
 8.  Th ong K.J., Norman J.E., Baird D.T.: Changes in the concentration of alpha-fetoprotein and placental 
hormones following two methods of medical abortion in early pregnancy. Br J Obstet Gynaecol. 
1993; 100: 1111–1114.
 9.  Bornstein E., Proudfi t C.L., Keeler S.M.: Prematurity in twin pregnancies; Minerva Ginecol. 2009; 61: 
113–126.
10. Hansen J.J., Bross P., Westergaard M., et al.: Genomic structure of the human mitochondrial 
chaperonin genes: HSP60 and HSP10 are localised head to head on chromosome 2 separated by 
a bidirectional promoter. Hum Genet. 2003; 112: 71–77.
11.  Smart T.C., Cripps A.W., Clancy R.L., Roberts T.K., Lopata A., Shutt D.A.: Detection of an 
immunosuppressive factor in human preimplantation embryo cultures. Med J Aust. 1981; 1: 78–79.
12.  Cheng S.J., Zheng Z.Q.: Early pregnancy factor in cervical mucus of pregnant women. Am J Reprod 
Immunol 2004; 51: 102–105.
13.  Zheng Z.Q., Qin Z.H., Ma A.Y., Qiao C.X., Wang H.: Detection of early pregnancy factor-like activity 
in human amniotic fl uid. Am J Reprod Immunol. 1990; 22: 9–11.
14. Wilcox A.J., Baird D.D., Weinberg C.R.: Time of implantation of the conceptus and loss of pregnancy. 
N Engl J Med. 1999; 340: 1796–1799.
15.  Cavanagh A.C., Morton H., Rolfe B.E., Gidley-Baird A.A.: Ovum factor: a fi rst signal of pregnancy? 
Am J Reprod Immunol. 1982; 2: 97–101.
16.  Morton H.: Early pregnancy factor (EPF): a link between fertilization and immunomodulation. Aust 
J Biol Sci. 1984; 37 (5–6): 393–407.
17.  Melle C., Bogumil R., Ernst G., Schimmel B., Bleul A., von Eggeling F.: Detection and identifi cation of 
heat shock protein 10 as a biomarker in colorectal cancer by protein profi ling. Proteomics. 2006; 6: 
2600–2608.
18.  Rappa F., Sciume C., Lo Bello M., et al.: Comparative analysis of Hsp10 and Hsp90 expression in 
healthy mucosa and adenocarcinoma of the large bowel. Anticancer Res. 2014; 34: 4153–4159.
19.  Têtu B., Popa I., Bairati I., et al.: Immunohistochemical analysis of possible chemoresistance markers 
identifi ed by micro-arrays on serous ovarian carcinomas. Mod Pathol. 2008; 21: 1002–1010.
20.  Johnson B.J., Le T.T., Dobbin C.A., et al.: Heat shock protein 10 inhibits lipopolysaccharide-induced 
infl ammatory mediator production. J Biol Chem. 2005; 280: 4037–4047.
21.  Qi Z., Shen L., Zhou H., et al.: Phosphorylation of heat shock protein 27 antagonizes TNF-a induced 
HeLa cell apoptosis via regulating TAK1 ubiquitination and activation of p38 and ERK signaling. 
Cell Signal. 2014; 26: 1616–1625.
22.  Rai R., Chauhan S.K., Singh V.V., Rai M., Rai G.: Heat shock protein 27 and its regulatory molecules 
express diff erentially in SLE patients with distinct autoantibody profi les. Immunol Lett. 2015; 164: 
25–32.
23. Olesińska M., Wiesik-Szewczyk E., Chwalińska-Sadowska H.: Evaluation of systemic lupus 
erythematosus activity during pregnancy. Pol Arch Med Wewn. 2007; 117: 312–316.
24. Gilmore T.D.: Introduction to NF-kappa-B:players, pathways, perspectives. Oncogene. 2006; 25: 
6680–6684.
25. Perkins N.D.: Integrating cell-signalling pathways witk NF-kappaB and IKK function. Nat Rev Mol 
Cell Biol. 2007; 8: 49–62.
50 Agnieszka Rajtar-Ciosek, Jakub Wyroba, et al.
26. Abdulsid A., Fletcher A., Lyall F.: Heat shock protein 27 is spatially distributed in the human placenta 
and decreased during labor. Plos one. 2013; 8 e71127.
27. Ha C.T., Wu J.A., Irmac S., et al.: Human pregnancy specific beta-1-glycoprotein1(PSG1) has 
a potential role in placental vascular morphogenesis. Biol Reprod. 2010; 83: 27–35.
28. Moore T., Dveksler G.S.: Pregnancy-specific glycoproteins: complex gene families regulating 
maternal-fetal interactions. Int J Dev Biol. 2014; 58: 273–280.
29. Ha C.T., Waterhouse R., Warren J., Zimmermann W., Dveksler G.S.: Binding of pregnancy-specifi c 
glycoprotein 17 to CD9 on macrophages induce secretion of IL-10, IL-6, PGE2, and TGF-beta1. 
J Leukoc Biol. 2005; 77: 948–957.
30. Pihl K., Larsen T., Laursen I., Krebs L., Christiansen M.: First trimester maternal serum pregnancy-
specifi c beta-1-glycoprotein (SP1) as a marker of adverse pregnancy outcome. Prenat Diag. 2009; 29: 
1256–1261.
31. Salem H.T., Lee I.N., Seppala M., et al.: Measurement of placental protein 5, placental lactogen 
and pregnancy-specifi c beta1 glycoprotein in mid trimester as predictor of outcome of pregnancy. 
Br J Obstet Gynaecol. 1981; 88: 371–374.
32. Bersinger N.A., Odegard R.A.: Second and third-trimester serum levels of placental proteins in 
preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand. 2004; 83: 37–45.
33. Wyroba J., Krzysiek J., Rajtar-Ciosek A., et al.: High live birth rate aft er conservative treatment of 
ectopic pregnancy with metotrexate. Ginekol Pol. 2014; 85: 105–110.
